Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, today announced that it has signed a letter of intent (“LOI”) to acquire Quantitative Medicine (“QM”), a biomedical analytics and computational biology company. By combining QM’s CoRE predictive modeling platform with POAI’s tumor profiling proficiency and data, company management believes the acquisition will assist in fast-tracking the commercialization of its AI-driven technology and services. Subject to the negotiation of a definitive agreement and other terms and conditions, the transaction is anticipated to be completed within the first two quarters of 2020. “Our goal is to provide researchers in pharma, biopharma and diagnostic companies’ with actionable insights that will not only drive the development of new precision therapies, companion diagnostics, and biomarkers, but will also help them design better targeted trials,” Predictive Oncology president and CEO Dr. Carl Schwartz stated in the news release. “Working together, we have the potential to dramatically improve patient outcomes.”
To view the full press release, visit http://ibn.fm/uIAbM
About Predictive Oncology
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient-derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.